Actively Recruiting
VHAG in Treating R/R T-ALL/LBL
Led by First Affiliated Hospital of Zhejiang University · Updated on 2024-12-19
50
Participants Needed
1
Research Sites
186 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Acute T cell lymphoblastic leukemia/lymphoma (T-ALL/LBL) is an aggressive type of leukemia that results from the malignant evolution of T-lineage progenitor cells at different differentiation stages. After induction chemotherapy and consolidation chemotherapy, there are still about 30% of patients who cannot achieve complete remission of clinical symptoms or negative MRD. This is also an important factor for the recurrence of ALL patients. In addition, most relapsed T-ALL/LBL patients relapse during first-line treatment. Once the disease relapses, it is difficult to cure for most young and adult patients, and the overall survival rate of patients is less than 10%.
CONDITIONS
Official Title
VHAG in Treating R/R T-ALL/LBL
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Diagnosis of newly diagnosed T-cell acute leukemia/lymphoma based on 2022 WHO classification
- Age 14 years or older and under 75 years
- Clinically diagnosed as relapsed or refractory T-ALL/LBL
- ECOG performance status score of 0 to 2
- Expected survival time of 2 months or more
- No organ dysfunction restricting protocol use during screening
- Able to understand the study and provide informed consent
You will not qualify if you...
- Known central nervous system involvement of T-ALL/LBL
- Abnormal heart, lung, liver, kidney, or other organ functions limiting trial participation
- Cardiac ultrasound showing left ventricular ejection fraction (LVEF) below 45%
- History of other malignancies within the past 5 years except localized thyroid cancer or in situ skin cancer
- Serum total bilirubin over 1.5 times the upper limit of normal
- ALT or AST over 2.5 times the upper limit of normal
- Serum creatinine over 1.5 times the upper limit of normal
- Known HIV infection
- Conditions affecting use of the study drug as judged by the investigator
- Inability to understand or comply with the study protocol
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
The First Affiliated Hospital, Zhejiang University School of Medicine
Hangzhou, Zhejiang, China, 310003
Actively Recruiting
Research Team
J
Jie Jin, M.D.
CONTACT
C
Chenying Li, Ph.D.
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here